Navigation Links
Media Alert: Discovery Labs to Hold Conference Call to Discuss FDA Approval of SURFAXIN® (lucinactant)
Date:3/7/2012

WARRINGTON, Pa., March 7, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, will hold a conference call for investors today at 10 a.m. EST to discuss its March 6th announcement that SURFAXIN (lucinactant) has been approved by the FDA for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS.  SURFAXIN is the first FDA-approved synthetic, peptide-containing surfactant.

The call-in number is (877) 215-0093. The international call in number is (706) 679-3237.  The passcode is 58400332. This audio webcast will be available through a live broadcast on the Internet at http://us.meeting-stream.com/discoverylaboratories_030212 and www.discoverylabs.com. The replay number to hear the conference call is (855) 859-2056 or (404) 537-3406 using the same conference call password listed above.

IMPORTANT SAFETY INFORMATION

SURFAXIN (lucinactant intratracheal suspension) is intended for intratracheal use only.  The administration of exogenous surfactants, including SURFAXIN, can rapidly affect oxygenation and lung compliance.  SURFAXIN should be administered only by clinicians trained and experienced with intubation, ventilator management, and general care of premature infants in a highly supervised clinical setting. Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.

Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption.  During SURFAXIN administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant's clinical condition assessed and stabilized. SURFAXIN is not indicated for use in acute respiratory distress syndrome (ARDS).

For more information about SURFAXIN, please visit www.surfaxin.com.


'/>"/>
SOURCE Discovery Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
2. Hospital to Hold MRSA Briefing for Media and Community Leaders
3. Superbug Outbreak Calls for Immediate Increased Attention on Infection Control
4. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
5. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
6. Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
8. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
9. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
10. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
11. New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)...  The particle counters market is projected to ... 275.9 million in 2016, at a CAGR of ... http://www.reportlinker.com/p04718602-summary/view-report.html The growing pharmaceutical and ... growth in manufacturing industries in emerging nations are ... counters. On the other hand, technical limitations of ...
(Date:2/24/2017)... 2017 Research and Markets has announced the ... - 2016" report to their offering. ... The latest research Urinary Incontinence Drugs ... benchmarks in the global Urinary Incontinence market. The research answers ... key drugs marketed for Urinary Incontinence and their clinical attributes? How ...
(Date:2/23/2017)... -- Genesis Healthcare Services has merged with Hospice Cloud, a ... Bill Monast , President and CEO of Hospice Cloud ... , executives with Home Health Depot, Inc., the parent ... This acquisition helps Hospice Cloud maintain its position as ... equipment (DME) solutions for the hospice industry. Nathan ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... ... Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced that he will ... the Management Committee when IFN was originally formed in 2002 where he was ultimately ... of the business plan. He became the first paid employee of IFN in ...
(Date:2/24/2017)... MI (PRWEB) , ... February 24, 2017 , ... ... in Charlevoix, once again hosted their Military Wedding Giveaway, with the winning ... hosted by Castle Farms with services generously donated from local vendors: A Matter ...
(Date:2/23/2017)... FL (PRWEB) , ... February 23, 2017 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – will return to the La Gorce Country Club in Miami Beach to ...
(Date:2/23/2017)... ... 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, dentist in ... the month of February, patients who visit Hamlin Dental Group will receive a ticket ... two at the Cheesecake Factory. , Tickets are available for routine dental visits ...
(Date:2/23/2017)... ... ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located at 10075 ... Patient Rated Henderson Dentist by Find Local Doctors earlier this year. ... who have earned high ratings and superior patient reviews from multiple credible sources. , ...
Breaking Medicine News(10 mins):